S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Pro-Dex Stock Forecast, Price & News

+0.14 (+0.88%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
6,130 shs
Average Volume
9,169 shs
Market Capitalization
$58.23 million
P/E Ratio
Dividend Yield
Price Target

Pro-Dex Stock Forecast (MarketRank)

Analyst Rating
0.00 Rating Score
86.5% Upside
$30.00 Price Target
Short Interest
0.52% of Float Sold Short
Dividend Strength
News Sentiment
1.24mentions of Pro-Dex in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.60 out of 5 stars

Medical Sector

916th out of 1,429 stocks

Surgical & Medical Instruments Industry

98th out of 138 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive PDEX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter.

Pro-Dex logo

About Pro-Dex (NASDAQ:PDEX)

Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.

PDEX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
0 Analysts


Net Income
$4.45 million
Pretax Margin


Sales & Book Value

Annual Sales
$38.03 million
Cash Flow
$1.47 per share
Book Value
$5.50 per share


Free Float
Market Cap
$58.23 million
Not Optionable

Pro-Dex Frequently Asked Questions

What is Pro-Dex's stock price forecast for 2022?

0 equities research analysts have issued 12 month price targets for Pro-Dex's shares. Their PDEX stock forecasts range from $30.00 to $30.00. On average, they anticipate Pro-Dex's stock price to reach $30.00 in the next year. This suggests a possible upside of 86.5% from the stock's current price.
View analysts' price targets for Pro-Dex
or view top-rated stocks among Wall Street analysts.

How has Pro-Dex's stock price performed in 2022?

Pro-Dex's stock was trading at $23.21 on January 1st, 2022. Since then, PDEX shares have decreased by 30.7% and is now trading at $16.09.
View the best growth stocks for 2022 here

When is Pro-Dex's next earnings date?

Pro-Dex is scheduled to release its next quarterly earnings announcement on Thursday, August 25th 2022.
View our earnings forecast for Pro-Dex

How were Pro-Dex's earnings last quarter?

Pro-Dex, Inc. (NASDAQ:PDEX) posted its earnings results on Thursday, May, 5th. The medical instruments supplier reported $0.12 earnings per share for the quarter. The medical instruments supplier earned $9.27 million during the quarter. Pro-Dex had a net margin of 8.50% and a trailing twelve-month return on equity of 15.41%.
View Pro-Dex's earnings history

Who are Pro-Dex's key executives?

Pro-Dex's management team includes the following people:
  • Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 61, Pay $416.15k)
  • Ms. Alisha K. Charlton, CFO & Corp. Sec. (Age 52, Pay $242.53k) (LinkedIn Profile)
  • Ms. Angel Rebamontan Domingo, Director and Director of Regulatory Affairs & Quality Assurance

What is Michael J. Berthelot's approval rating as Pro-Dex's CEO?

3 employees have rated Pro-Dex CEO Michael J. Berthelot on Glassdoor.com. Michael J. Berthelot has an approval rating of 85% among Pro-Dex's employees.

What other stocks do shareholders of Pro-Dex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pro-Dex investors own include KEMET (KEM), NVIDIA (NVDA), Enterprise Products Partners (EPD), Micron Technology (MU), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA), Bank of America (BAC), Marvell Technology (MRVL) and UnitedHealth Group (UNH).

What is Pro-Dex's stock symbol?

Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."

How do I buy shares of Pro-Dex?

Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pro-Dex's stock price today?

One share of PDEX stock can currently be purchased for approximately $16.09.

How much money does Pro-Dex make?

Pro-Dex (NASDAQ:PDEX) has a market capitalization of $58.23 million and generates $38.03 million in revenue each year. The medical instruments supplier earns $4.45 million in net income (profit) each year or $0.87 on an earnings per share basis.

How many employees does Pro-Dex have?

Pro-Dex employs 117 workers across the globe.

How can I contact Pro-Dex?

Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The official website for Pro-Dex is www.pro-dex.com. The medical instruments supplier can be reached via phone at (949) 769-3200, via email at investor.relations@pro-dex.com, or via fax at 949-769-3281.

This page (NASDAQ:PDEX) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.